Viracept was launched in the US as an orally-available, non-peptidic HIV
protease inhibitor. It is prepared in an eight step synthesis beginning with N-
(benzyloxycarbonyl)-L-serine β-lactone. The HIV protease inhibitory activity blocks the
processing of gag and gagpol polyproteins that are required for viral maturation. It
was discovered based on an experimentally derived 3D-structure of HIV-1 protease.
Viracept has a high oral bioavailability, lacks toxicity, and has a resistance profile
different from other protease inhibitors. Viracept with ziduvudine and larnivudine
generated a 98% mean reduction from baseline in viral load after 24 weeks compared
to ziduvudine and larnivudine alone. Viracept also had better CD4 counts and is
available in adult and pediatric formulations.
화학적 성질
White Powder
용도
Nelfinavir Mesylate is an antiviral. HIV protease inhibitor. It is a COVID19-related research product.
정의
ChEBI: A methanesulfonate (mesylate) salt prepared from equimolar amounts of nelfinavir and methanesulfonic acid. It is used for treatment of HIV and also exhibits some anticancer properties.
생물학적 활성
Orally active human immunodeficiency virus protease inhibitor. Potently inhibits HIV-1 protease (K i = 2 nM) in vitro .
